Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPATCH: Proteomics and Pharmacokinetics of Adriamycin Following Different Chemoembolisation Techniques in Hepatocellular Carcinoma
2005-000163-25Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- May 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by University of Birmingham. Primary endpoints: Doxorubicin AUC and Doxorubicin Cmax. Started May 2005; status: completed.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2005-000163-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000163-25.